A Phase II, Double-Blind, Placebo Controlled, Randomized Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy

Status
Active
Cancer Type
Breast Cancer
Trial Phase
Phase II
Eligibility
18 and over, Female
Study Type
Treatment
NCD ID
NCT01437566
Protocol IDs
GDC4950g (primary)
GO00769
Study Sponsor
Genentech Incorporated

Summary

This is a multicenter, international, randomized, double-blinded, placebo-controlled, Phase II trial with three study arms. Patients with advanced or Metastatic Breast Cancer (MBC) whose disease is resistant to aromatase inhibitor (AI) therapy will be enrolled in this study.